Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 37 of 37 entries
View as:

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05194735 Org: User:
Start: 04/04/22 End: 11/30/24 Due: 11/30/25

A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b

Phase: N/A Priority: Normal
NCT ID: NCT00423644 Org: User:
Start: 01/31/07 End: 12/31/13 Due: 12/31/14

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02423902 Org: User:
Start: 07/31/15 End: 07/31/16 Due: 07/31/17

HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05124743 Org: User:
Start: 09/24/21 End: 05/28/28 Due: 05/28/29

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01397708 Org: User:
Start: 08/31/11 End: 09/30/14 Due: 09/30/15

Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT01703754 Org: User:
Start: 03/31/13 End: 12/31/14 Due: 12/31/15

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT04006119 Org: User:
Start: 08/01/19 End: 08/05/21 Due: 08/05/22

Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT00592163 Org: User:
Start: 12/31/07 End: 06/30/13 Due: 06/30/14

Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT01168791 Org: User:
Start: 07/31/10 End: 03/31/13 Due: 03/31/14

A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00718484 Org: User:
Start: 08/31/08 End: 04/30/14 Due: 04/30/15

Study of Oral Palifosfamide Tris in Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00607711 Org: User:
Start: 03/31/08 End: 11/30/09 Due: 11/30/10

Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01340547 Org: User:
Start: 06/30/11 End: 09/30/13 Due: 09/30/14